IMAI MedTech

About IMAI MedTech

IMAI MedTech manufactures an automated 3D histology platform that accelerates tissue staining and processing from weeks to hours, enhancing diagnostic accuracy in cancer detection. Their technology reduces false negatives and improves patient outcomes by providing detailed 3D visualization and quantitative analysis of tissue samples.

```xml <problem> Traditional 2D histology methods can lead to information loss and false negatives in cancer detection due to their limited ability to visualize the full tissue structure. Manual tissue staining and processing are also time-consuming, often taking weeks to complete. </problem> <solution> IMAI MedTech offers an automated 3D histology platform that accelerates tissue staining and processing, reducing the preparation time from weeks to hours. The platform provides detailed 3D visualization and quantitative analysis of tissue samples, enhancing diagnostic accuracy in cancer detection. By leveraging advanced detection technologies, the platform significantly reduces false negatives, leading to more accurate diagnoses and improved patient outcomes. The system's automation and precision contribute to a higher cell detection rate and more comprehensive examination of tissue characteristics. </solution> <features> - Automated tissue staining and clearing protocols for rapid 3D histology - Compatibility with light-sheet microscopy for high-resolution 3D imaging - Advanced image analysis software for efficient 3D sample interaction and visualization - Quantitative analysis of tissue structures and cellular arrangements - Automated and precise methodologies to ensure a higher cell detection rate - Potential to improve treatment outcomes through early and precise cancer cell detection </features> <target_audience> The primary customers are researchers, cancer diagnostic centers, and healthcare providers seeking to improve the speed and accuracy of tissue analysis for cancer detection. </target_audience> ```

What does IMAI MedTech do?

IMAI MedTech manufactures an automated 3D histology platform that accelerates tissue staining and processing from weeks to hours, enhancing diagnostic accuracy in cancer detection. Their technology reduces false negatives and improves patient outcomes by providing detailed 3D visualization and quantitative analysis of tissue samples.

Where is IMAI MedTech located?

IMAI MedTech is based in Schlieren, Schweiz/Suisse/Svizzera/Svizra.

When was IMAI MedTech founded?

IMAI MedTech was founded in 2024.

How much funding has IMAI MedTech raised?

IMAI MedTech has raised 220000.

Who founded IMAI MedTech?

IMAI MedTech was founded by Robert Axelrod and Sascha Brun.

  • Robert Axelrod - Co-founder/CEO
  • Sascha Brun - Co-Founder
Location
Schlieren, Schweiz/Suisse/Svizzera/Svizra
Founded
2024
Funding
220000
Employees
9 employees
Major Investors
Venture Kick
Looking for specific startups?
Try our free semantic startup search

IMAI MedTech

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

IMAI MedTech manufactures an automated 3D histology platform that accelerates tissue staining and processing from weeks to hours, enhancing diagnostic accuracy in cancer detection. Their technology reduces false negatives and improves patient outcomes by providing detailed 3D visualization and quantitative analysis of tissue samples.

imai-medtech.com500+
cb
Crunchbase
Founded 2024Schlieren, Schweiz/Suisse/Svizzera/Svizra

Funding

$

Estimated Funding

$220K+

Major Investors

Venture Kick

Team (5+)

Robert Axelrod

Co-founder/CEO

Sascha Brun

Co-Founder

Company Description

Problem

Traditional 2D histology methods can lead to information loss and false negatives in cancer detection due to their limited ability to visualize the full tissue structure. Manual tissue staining and processing are also time-consuming, often taking weeks to complete.

Solution

IMAI MedTech offers an automated 3D histology platform that accelerates tissue staining and processing, reducing the preparation time from weeks to hours. The platform provides detailed 3D visualization and quantitative analysis of tissue samples, enhancing diagnostic accuracy in cancer detection. By leveraging advanced detection technologies, the platform significantly reduces false negatives, leading to more accurate diagnoses and improved patient outcomes. The system's automation and precision contribute to a higher cell detection rate and more comprehensive examination of tissue characteristics.

Features

Automated tissue staining and clearing protocols for rapid 3D histology

Compatibility with light-sheet microscopy for high-resolution 3D imaging

Advanced image analysis software for efficient 3D sample interaction and visualization

Quantitative analysis of tissue structures and cellular arrangements

Automated and precise methodologies to ensure a higher cell detection rate

Potential to improve treatment outcomes through early and precise cancer cell detection

Target Audience

The primary customers are researchers, cancer diagnostic centers, and healthcare providers seeking to improve the speed and accuracy of tissue analysis for cancer detection.

IMAI MedTech - Funding: $200K+ | StartupSeeker